Notification of trade by Agrinos co-founder

The following share trade in Agrinos AS was carried out on July 8th, 2013:

Korrigan Investment AS, a company associated to Agrinos co-founder and Director of Strategic Development Aaron Powers, sold 190,000 shares in Agrinos AS at an average price of NOK 20.75 per share. The transaction was carried out to settle US and Norwegian tax obligations and related costs in connection with Korrigan Investment’s (and, indirectly, Mr. Powers’) share holdings in Agrinos. 

After the transaction, Korrigan Investment AS has a holding of 3,865,969 shares in Agrinos AS corresponding to 8.66% of the outstanding shares in the company.

For further information, please contact:
Harald Bjørland
EVP Corporate Communications and Investor Relations
+47 908 58 221
harald.bjoerland@agrinos.com

About Agrinos

Agrinos is a biological crop input provider committed to improving the productivity and sustainability of modern agriculture. Agrinos’ range of High Yield Technology^® (“HYT^®”) products helps farmers to practice profitable agriculture by providing increased crop productivity, improved efficiency of conventional fertilizer and a reduced environmental footprint. 

Certified as organic and based on Agrinos’ proprietary technology, the HYT^® products provide benefits by strengthening the soil-based microbial ecosystem, stimulating crop development at key points in the growth cycle and boosting natural plant resistance to pathogens and threats. With solutions for a variety of crop categories, the technology comprising the HYT^® products has demonstrated its value in third-party trials in key agricultural regions worldwide. Founded in 2009, Oslo-based Agrinos has more than 300 employees and has grown to include activities in Mexico, the USA, Colombia, Peru, Brazil, the UK, Spain, the Nordics, Ghana, Malaysia, Indonesia, India and the People’s Republic of China. Agrinos enjoys financial backing from a number of leading international investors and has a strong management team led by its chairman, Dr Thorleif Enger.